Early Tumor Shrinkage Points to Good Erbitux Outcomes

Patients with advanced colorectal cancer whose tumors have gotten smaller six weeks after starting treatment with Erbitux had a much longer time before their cancer got worse and almost twice the overall survival as patients whose tumors didn’t shrink. Patients…  Read More

Lack of Insurance Impacts Survival in CRC Patients Under 65.

Not having insurance reduces the chance that someone with colorectal cancer will live a year after their diagnosis.  Even when patients from 18 to 64 have other illnesses, their insurance status makes a difference in survival. Risk of dying during…  Read More

Adding Irinotecan to Infusional 5-FU Does Not Add Benefit for Stage III Colon Cancer

Five years after surgery, there was no improvement in either disease-free survival or overall survival when irinotecan was added to standard 5-FU treatments delivered via continous infusion for patients with stage III colon cancer.  Adding irinotecan increased the rate of…  Read More

Tumor Mutation Predicts Poor Prognosis in Stage I-III Colon Cancer

By studying changes in tumor tissue from colon cancer patients whose cancers had not spread to distant organs, researchers were able to isolate a gene mutation that led to a poor outcome. Stage I through III colon cancer patients whose…  Read More